PhaseV, a Tel Aviv, Israel and Boston, MA-based company which specializes in causal machine learning (ML) technology that optimizes clinical trial design and analysis, raised $15M in funding.
The round was led by Viola Ventures and Exor Ventures, including participation from LionBird and a group of prominent angel investors.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Dr. Raviv Pryluk, PhaseV leverages advanced causal inference to detect hidden signals in clinical data and extracts actionable insights for planning the optimal next steps. The company uses proprietary ML technology that provides clinical development teams an advanced ability to retrospectively analyze and optimally design studies, as well as adapt in real-time throughout the trial. This ML-driven adaptive process can accelerate the clinical drug development process and increase certainty along the way, resulting in more efficient, targeted, and more successful clinical trials.
PhaseV offers two distinct service lines for AI clinical trial optimization. The first includes assessing the potential impact of adaptive trial design on the proposed study, followed by optimal design and execution. The second involves retrospective analysis that detects hidden signals in clinical trial data and evaluates endpoints and subpopulations to redefine success or failure of a trial. Leveraging a wide range of parameters, this approach is also valuable for drug repurposing efforts. The company’s approach has proven valuable in a variety of therapeutic areas including oncology, endocrinology, autoimmune diseases, rare diseases and more.
FinSMEs
24/10/2023